TAK-279-PsA-3002 Enrolling

Active Psoriatic Arthritis Research Trial (60 Weeks)


Treatment: Oral Age: 18+ Years


Who Can Participate?

Adults aged 18 years or older with psoriatic arthritis (PsA) may be eligible to participate.

 

Inclusion Criteria:

      • Signs and symptoms consistent with PsA for at least 3 months
      • Active arthritis as shown by a minimum of ≥ 3 tender joints and ≥ 3 swollen joints
      • At least 1 active lesion of plaque psoriasis ≥ 2 cm in diameter, or any nail or nail bed changes characteristic of psoriasis
      • Have had at least one of the following:
          • inadequate response to an NSAID after a minimum of 2 weeks of therapy, OR
          • inadequate response to a csDMARD and/or apremilast after a minimum of 12 consecutive weeks of therapy, or intolerance to a csDMARD and/or apremilast, OR
          • inadequate response to up to 2 biologic DMARDs (up to 2 TNFi OR up to 2 IL-17i) after a minimum of 12 consecutive weeks of therapy, or intolerance to up to 2 biologic DMARDs

 

Participant Info:

      • No cost to participate or receive treatment
      • Regular visits with study doctors who specialise in treating psoriatic arthritis
      • Will receive investigational oral treatment (active study drug) or placebo, during the placebo-controlled period
      • Reimbursement for study-related expenses may be provided

 

How Long Will The Study Last?

      • 60 weeks and involve about 14 visits to the study research site

Participating Locations

COUNTRY
country-icon
Canada

Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: May 01, 2025

Official Title

A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002)

ClinicalTrials.gov ID

NCT06671496

Sponsor

Takeda

Study Description

  • Brief Summary:

    Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments. The participants will be treated with either zasocitinib, or placebo. Participants will be in the study for up to 60 weeks.

  • Condition or Disease:

    Psoriatic Arthritis

  • Intervention/Treatment:

    Drug: Zasocitinib Drug: Zasocitinib Drug: Zasocitinib,Drug: Placebo
  • Phase:

    PHASE 3

  • Ages Eligible for Study:

    18 Years and older (ADULT,OLDER_ADULT)

  • Sexes Eligible for Study:

    ALL


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Psoriasis and Psoriatic Disorders

Adults aged 18 to 75 years old diagnosed with plaque psoriasis for at least 6 months, may qualify to participate.... Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content